Publications by authors named "Alysia Polito"
Seventy-six FDA-approved oncology drugs and emerging therapeutics were evaluated in 25 multiple myeloma (MM) and 15 non-Hodgkin's lymphoma cell lines and in 113 primary MM samples. Ex vivo drug sensitivities were mined for associations with clinical phenotype, cytogenetic, genetic mutation, and transcriptional profiles. In primary MM samples, proteasome inhibitors, dinaciclib, selinexor, venetoclax, auranofin, and histone deacetylating agents had the broadest cytotoxicity.
View Article and Find Full Text PDFArticle Synopsis
- APY0201, a PIKfyve inhibitor, shows strong cellular cytotoxicity against multiple myeloma, confirmed through testing in 25 cell lines and 40% of 100 primary patient samples, especially in cases with trisomies and without t(11;14).
- When compared to other PIKfyve inhibitors, APY0201 demonstrated superior potency, effectively reducing cell viability at very low concentrations in a majority of tested cell lines.
- The treatment with APY0201 resulted in changes related to lysosomal function and autophagy, suggesting that its effectiveness in multiple myeloma may stem from disrupting these cellular processes, and establishing a predictive autophagy assay could help identify likely responsive patients.
Quiescin sulfhydryl oxidase 1 (QSOX1) is an enzyme overexpressed by many different tumor types. QSOX1 catalyzes the formation of disulfide bonds in proteins. Because short hairpin knockdowns (KD) of QSOX1 have been shown to suppress tumor growth and invasion and , we hypothesized that chemical compounds inhibiting QSOX1 enzymatic activity would also suppress tumor growth, invasion, and metastasis.
View Article and Find Full Text PDF